Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell
In This Article:
Corvus Pharmaceuticals (CRVS) said Wednesday that interim results from a phase 1 trial of its experi
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.